Neurology

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory…

3 months ago

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.  FREMONT, Calif., Oct. 9,…

3 months ago

Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions

TIME Best Inventions honors extraordinary innovations changing lives DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader…

3 months ago

Kneu Health Secures $5.6M to Scale Next-Generation Neurology Care

Built on one of the world's largest Parkinson's and dementia datasets and adopted across major U.S. health systems and NHS Trusts,…

3 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the…

3 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the…

3 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the…

3 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Event to be held October 14th at 4 p.m. ESTBETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc.…

3 months ago

Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer

MILAN, Italy, October 09, 2025 – Italfarmaco S.p.A. today announced that Dr. Francesco Di Marco has been appointed as Chief…

3 months ago

Theranica Brings First-in-Class, Drug-Free Migraine Care to the Forefront at CNS 2025 with Product Theater and New Real-World Evidence

With a dedicated product theater and new real-world evidence posters, Theranica will spotlight how the Nerivio® REN wearable is reshaping…

3 months ago